S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:TGTX

TG Therapeutics - TGTX Stock Forecast, Price & News

$7.44
-0.08 (-1.06%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.18
$7.76
50-Day Range
$3.74
$7.52
52-Week Range
$3.48
$35.94
Volume
4.03 million shs
Average Volume
2.89 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25

TG Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
185.6% Upside
$21.25 Price Target
Short Interest
Bearish
28.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.28mentions of TG Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.10) to ($1.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

772nd out of 1,098 stocks

Pharmaceutical Preparations Industry

379th out of 536 stocks

TGTX stock logo

About TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics Trading Down 1.1 %

Shares of TGTX Stock opened at $7.44 on Wednesday. TG Therapeutics has a fifty-two week low of $3.48 and a fifty-two week high of $35.94. The stock's fifty day moving average price is $5.24 and its two-hundred day moving average price is $7.57. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.43 and a current ratio of 4.43. The company has a market cap of $1.07 billion, a PE ratio of -3.04 and a beta of 2.28.

TG Therapeutics (NASDAQ:TGTX - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.04. The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $1.54 million. TG Therapeutics had a negative return on equity of 118.49% and a negative net margin of 4,126.45%. Equities analysts predict that TG Therapeutics will post -2.1 EPS for the current fiscal year.

Analyst Ratings Changes

TGTX has been the subject of a number of recent research reports. Bank of America began coverage on shares of TG Therapeutics in a report on Friday, May 20th. They issued an "underperform" rating for the company. HC Wainwright cut their price target on TG Therapeutics from $68.00 to $19.00 and set a "buy" rating for the company in a research note on Monday, April 18th. StockNews.com upgraded TG Therapeutics to a "sell" rating in a research note on Friday, June 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of TG Therapeutics in a report on Monday, May 9th. Finally, B. Riley dropped their price target on TG Therapeutics from $23.00 to $17.00 and set a "buy" rating for the company in a research note on Monday, June 13th. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, TG Therapeutics has a consensus rating of "Hold" and a consensus price target of $21.25.

Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Stock News Headlines

Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $21.25
TG Therapeutics (NASDAQ:TGTX) Shares Down 5.3%
TG Therapeutics (NASDAQ:TGTX) Shares Down 2.7%
5 Analysts Have This to Say About TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) Is Using Debt Safely
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
286
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.25
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+185.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-348,100,000.00
Net Margins
-4,126.45%
Pretax Margin
-4,126.47%

Debt

Sales & Book Value

Annual Sales
$6.69 million
Book Value
$1.68 per share

Miscellaneous

Free Float
132,014,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
2.28














TGTX Stock - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TGTX, but not buy additional shares or sell existing shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price forecast for 2022?

6 brokers have issued 12-month price objectives for TG Therapeutics' shares. Their TGTX share price forecasts range from $13.00 to $36.00. On average, they predict the company's stock price to reach $21.25 in the next twelve months. This suggests a possible upside of 185.6% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How has TG Therapeutics' stock price performed in 2022?

TG Therapeutics' stock was trading at $19.00 at the beginning of 2022. Since then, TGTX stock has decreased by 60.8% and is now trading at $7.44.
View the best growth stocks for 2022 here
.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.09. The biopharmaceutical company earned $2.03 million during the quarter, compared to the consensus estimate of $3.23 million. TG Therapeutics had a negative trailing twelve-month return on equity of 118.49% and a negative net margin of 4,126.45%. During the same quarter in the previous year, the business posted ($0.73) EPS.

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.45%), Swiss National Bank (0.22%), Walleye Capital LLC (0.14%), Hennion & Walsh Asset Management Inc. (0.13%), Simplex Trading LLC (0.00%) and Los Angeles Capital Management LLC (0.09%). Insiders that own company stock include Michael S Weiss, Ra Capital Management, LP, Sean A Power, William James Kennedy and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $7.44.

How much money does TG Therapeutics make?

TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $1.07 billion and generates $6.69 million in revenue each year. The biopharmaceutical company earns $-348,100,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

How many employees does TG Therapeutics have?

TG Therapeutics employs 286 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531.

This page (NASDAQ:TGTX) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.